About this trial
This study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths, low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is poor adherence with LCS by patients. Both provider and patient barriers may be amenable to systemic improvements in support, coordination and infrastructure for screening. The investigator team hypothesizes that the implementation of a Central Screening Unit (CSU) that shifts routine workflow attributed to LCS (e.g., collection of smoking history, determination of eligibility, shared decision making and arranging follow-up) away from busy practices (usual care) and that offers patients an array of navigation and support services will increase the uptake of LCS guidelines and subsequent low-dose computed tomography (LDCT) screening scans in a low-income, predominately Hispanic and Black catchment area. The proposed study represents a unique opportunity to test this hypothesis in the context of the roll out of a CSU as a significant new component of the Montefiore-Einstein health system. The investigator team will examine whether and how the CSU facilitates LCS uptake and retention of patients. This study is powered to test whether CSU reduces proportion of late-stage lung cancer diagnoses in the Bronx, New York.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
a NYC RING affiliated clinic,
Opt into and agree to research protocol;
Age 50-77 for participants,
past or current smoker,
Disqualifiers
only treats pediatric patients,
Opt out of research protocol;
Primary care provider instruction to not contact an individual for any reason. Any individual inadvertently contacted who does not meet these criteria will be excluded from the study.
Trial design
Parallel
Treatments tested in this trial
Centralized Screening Unit Implementation
Other interventionThe CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
Treatment groups
Trial outcomes
Primary outcomes
Participant Referrals
The number of participant referrals by clinician for LCS by the CSU versus the number of clinician referrals will be assessed and reported.
Proportion of participants with early stage lung cancer (LCa)
The proportion of participants with early stage LCa disease (for the purposes of this study defined as any Stage 1 or Stage 2 LCa) amongst those who received LCS during the study period compared to those diagnosed in the general Einstein-Montefiore population during the same time period, including the 11 NYC RING clinics not in the trial, and the preceding 7 years (i.e., since LDCT has been available at MMC) will be assessed and reported.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Albert Einstein College of Medicine
Lead sponsor
American Cancer Society, Inc.
Collaborator